Please select the option that best describes you:
What are your top takeaways in GU Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: Medical Oncologist at Academic Institution
1. Bladder cancer. Potential new non-muscle invasive bladder cancer immunotherapy with N-803, an IL-15 superagonist plus BCG. Abstract 4508. Demonstrated striking complete and durable remissions (70%), bladder preservations over 1-2 years of follow up (>90% cystectomy free survival), favorable to...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
For urothelial cancer:1. 4508 (Chamie et al.) Take home: intravesical BCG+N-803 showed impressive safety & efficacy data in BCG-unresponsive high-risk NMIBC and may seek regulatory approval in that setting; caveat is the single arm (not randomized) trial design; we noted a few differences in the...
Answer from: Medical Oncologist at Community Practice
For bladder cancer only:1. QUILT3032- IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) (Abstract: 4508): Combination N803 + BCG (both intravesical) was active in the CIS group (n=84, CR 71%, 1-year CR 61.6%, median DOR 26.6 mo) and the p...